PortViewPortView
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals (SNOA) Stock Analysis

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$1.30+0.78%
1-year price historyRange $1.01 – $4.73
52-week range$1.30
$0.85$4.77

What Sonoma Pharmaceuticals does

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.

Key metrics

Market cap
$2.19M
P/E (TTM)
-1.10
EPS (TTM)
$-1.18
Beta
1.29
Dividend yield
0.00%
Revenue / share
$5.70
50-day avg
$1.24
200-day avg
$2.18
52-week high
$4.77
52-week low
$0.85
CEO
Amy Trombly

ETFs linked to SNOA

Broad-market and Healthcare sector ETFs an investor holding Sonoma Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SNOA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze SNOA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals trades under the ticker SNOA on NASDAQ.
Which exchange is SNOA listed on?
SNOA is listed on NASDAQ.
What sector does Sonoma Pharmaceuticals operate in?
Sonoma Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
How can PortView help analyze SNOA in a portfolio?
PortView shows SNOA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.